DAWN
Day One Biopharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.03
P/S
14.01
EV/EBITDA
-19.10
DCF Value
$56.24
FCF Yield
-4.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.1%
Operating Margin
-80.8%
Net Margin
-67.8%
ROE
-23.4%
ROA
-21.9%
ROIC
-28.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $53.7M | $-21.3M | $-0.21 |
| FY 2025 | $158.2M | $-107.3M | $-1.04 |
| Q3 2025 | $39.8M | $-19.7M | $-0.19 |
| Q2 2025 | $33.9M | $-30.3M | $-0.29 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-1.75
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.